Triple Genetic Alterations (EGFR Mutation, ALK Fusion, and MET Polysomy) in Gynecological Metastasis of Lung Adenocarcinoma Patient with Acquired Resistance to Furmonertinib: A Case Report.
- 1Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Abstract
For advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, targeted therapy is the standard first-line treatment, but acquired resistance and disease progression are inevitable. Identification of resistance mechanisms is crucial for guiding subsequent anti-tumor therapy. We report a 57-year-old female patient with advanced lung adenocarcinoma harboring an EGFR exon 21 L858R mutation. The patient experienced disease progression with rare gynecological metastasis after 16 months of first-line furmonertinib therapy. Next-generation sequencing (NGS) of the uterine metastatic lesion identified concurrence of EGFR mutation and ALK fusion, while fluorescence in situ hybridization (FISH) confirmed MET polysomy. The patient exhibited intolerance to the combination therapy of glumetinib plus furmonertinib. Subsequently, the patient received a combination of furmonertinib and the ALK-TKI ensartinib, which was assessed as a partial response (PR) at the first restaging evaluation (1 month after treatment initiation), with favorable safety and tolerability. Secondary ALK fusion may represent a rare but clinically meaningful resistance mechanism in EGFR-mutant NSCLC. Furthermore, while gynecological metastasis from lung cancer is uncommon, clinicians should be alert to this possibility in patients presenting with relevant symptoms, with pelvic examination conducted as needed.
Related
- Retrospective real-world associations between EGFR alterations and furmonertinib outcomes in advanced non-small cell lung cancer
- Leptomeningeal metastasis of lung adenocarcinoma presenting as cauda equina syndrome: a case report and literature review
- Orbital metastasis revealing occult metastatic prostate adenocarcinoma in a South African man: A rare initial ophthalmic presentation
- Villoglandular Adenocarcinoma of the Cervix With Ovarian Metastasis Mimicking a Borderline Ovarian Tumor: A Rare Case Report.
- Case of Appendiceal Goblet Cell Adenocarcinoma With Gastric Metastasis.
BibTeX
@article{jiang2026triple,
title = {{Triple Genetic Alterations (EGFR Mutation, ALK Fusion, and MET Polysomy) in Gynecological Metastasis of Lung Adenocarcinoma Patient with Acquired Resistance to Furmonertinib: A Case Report.}},
author = {Qinglong Jiang and Rui Sun and Haiyan Xu and Yanfeng Wang},
journal = {Current oncology (Toronto, Ont.)},
year = {2026},
month = oct,
doi = {10.3390/curroncol33100613},
url = {https://europepmc.org/article/MED/42930180},
note = {CC BY},
}
RIS
TY - JOUR
TI - Triple Genetic Alterations (EGFR Mutation, ALK Fusion, and MET Polysomy) in Gynecological Metastasis of Lung Adenocarcinoma Patient with Acquired Resistance to Furmonertinib: A Case Report.
AU - Qinglong Jiang
AU - Rui Sun
AU - Haiyan Xu
AU - Yanfeng Wang
PY - 2026
DA - 2026/10/12
JO - Current oncology (Toronto, Ont.)
DO - 10.3390/curroncol33100613
UR - https://europepmc.org/article/MED/42930180
AB - For advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, targeted therapy is the standard first-line treatment, but acquired resistance and disease progression are inevitable. Identification of resistance mechanisms is crucial for guiding subsequent anti-tumor therapy. We report a 57-year-old female patient with advanced lung adenocarcinoma harboring an EGFR exon 21 L858R mutation. The patient experienced disease progression with rare gynecological metastasis after 16 months of first-line furmonertinib therapy. Next-generation sequencing (NGS) of the uterine metastatic lesion identified concurrence of EGFR mutation and ALK fusion, while fluorescence in situ hybridization (FISH) confirmed MET polysomy. The patient exhibited intolerance to the combination therapy of glumetinib plus furmonertinib. Subsequently, the patient received a combination of furmonertinib and the ALK-TKI ensartinib, which was assessed as a partial response (PR) at the first restaging evaluation (1 month after treatment initiation), with favorable safety and tolerability. Secondary ALK fusion may represent a rare but clinically meaningful resistance mechanism in EGFR-mutant NSCLC. Furthermore, while gynecological metastasis from lung cancer is uncommon, clinicians should be alert to this possibility in patients presenting with relevant symptoms, with pelvic examination conducted as needed.
SN - 1198-0052
SN - 1718-7729
ER -